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Abstract: The ability of integrins to activate and integrate intracellular communication illustrates the
potential of these receptors to serve as functional distribution hubs in a bi-directional signal transfer
outside-in and inside-out of the cells. Tight regulation of the integrin signaling is paramount for
normal physiological functions such as migration, proliferation, and differentiation, and misregulated
integrin activity could be associated with several pathological conditions. Because of the important
roles of integrins and their ligands in biological development, immune responses, leukocyte traffic,
haemostasis, and cancer, their potential as therapeutic tools is now widely recognized. Nowadays
extensive efforts have been made to discover and develop small molecule ligands as integrin
antagonists, whereas less attention has been payed to agonists. In recent years, it has been
recognized that integrin agonists could open up novel opportunities for therapeutics, which gain
benefits to increase rather than decrease integrin-dependent adhesion and transductional events.
For instance, a significant factor in chemo-resistance in melanoma is a loss of integrin-mediated
adhesion; in this case, stimulation of integrin signaling by agonists significantly improved the
response to chemotherapy. In this review, we overview results about small molecules which revealed
an activating action on some integrins, especially those involved in cancer, and examine from
a medicinal chemistry point of view, their structure and behavior.
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1. Introduction
Integrins are cell surface receptors structurally comprised of non-covalent associations between α
and β subunits. Both subunits are type I transmembrane glycoproteins that contain a relatively large
extracellular domain, a single transmembrane domain, and a short cytoplasmic tail [1,2]. In mammals,
18 α subunits and eight β subunits are non-covalently associated to form 24 different integrin
αβ heterodimers expressed differently in particular tissues. In addition to this tissue specificity,
each integrin exhibits a distinct binding affinity to particular ligands (Figure 1) [3,4]. The α-subunits
have the greatest influence on ligand-binding specificity, and define different integrin families with
specificity for Arg-Gly-Asp (RGD) motifs (αIIb, αV, α5, and α8), intercellular adhesion molecules and
inflammatory ligands (α4, αL, αM, αX, and αD), collagens (α1, α2, α10, and α11), and laminins (α3, α6,
and α7).
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Figure 1. Classification of the 24 integrin heterodimers according to the combination of the subunits 
α and β, their specific ligands, or cell type. RGD: Arg-Gly-Asp. 
Integrins are not just adhesion receptors that mediate dynamic adhesive cell-cell and cell-matrix 
interactions, but they can transmit information on the chemical identity and physical state of their 
ligands into cells, to regulate cell migration, cell survival, and growth. The activation of intracellular 
signaling pathways controls cell shape, motility, proliferation, survival, and cell-type-specific gene 
expression [2]. Adhesion signaling via integrins is, therefore, a key contributor to both health and 
disease [5–7]. 
Integrins are normally inactive with low affinity for their endogenous ligands, but they undergo 
rapid activation upon various stimuli [8,9]. To convert integrins into active states with different 
ligand binding affinities, intracellular signaling (inside-out signaling) is required. As bidirectional 
receptors, integrins can also transmit signals back into cells: upon ligand binding in the extracellular 
domain, they transmit an outside-in signaling that regulates cell shape, migration, growth, and 
differentiation.  
The ability of integrins to bind and associate with various components of the extracellular matrix 
(ECM) or soluble ligands largely depends on the structural conformations of the two subunits α and 
β, and distinct conformations are crucial for regulating both inside-out and outside-in cell  
signaling [4,10,11].  
Concerning the integrin site for ligand binding and from a structural point of view, it is 
important to distinguish the two types of α-subunits in integrins: those with or those without an 
inserted domain, named the αI domain (Figure 2). In αI-integrins, the αI domain is the binding site 
for ligands, whereas in integrins without the αI domain, the ligand-binding site is formed at the 
interface between the α-subunit and the β-subunit in its βI domain [11]. Thus, in integrins without 
an αI domain, the β subunit contributes to modulate the ligand specificity. The αI and βI domains 
are structurally homologous and contain metal ion-dependent adhesion sites (MIDAS) which are able 
to bind Asp, Glu, or carboxylic acid residues in ligands. In RGD-binding integrins (without αI), the 
Arg of RGD binds the α-subunit while the Asp of RGD coordinates to the Mg2+ ion in the β subunit 
βI domain MIDAS. The elucidation of this mode of ligand binding explains the cation dependence of 
ligand binding and cell adhesion. 
Structural studies (crystallography, nuclear magnetic resonance, NMR, and electron microscopy 
studies) have revealed three overall conformational states: a bent, an extended-closed, and an 
extended-open conformations (Figure 2); these may correspond to a low affinity conformer, an 
activated, and an activated together with ligand-occupied integrin conformers, respectively [12].  
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Integrins are not just adhesion receptors that mediate dynamic adhesive cell-cell and cell-matrix
interactions, but they can transmit information on the chemical identity and physical state of their
ligands into cells, to regulate cell migration, cell survival, and growth. The activation of intracellular
signaling pathways controls cell shape, motility, proliferation, survival, and cell-type-specific gene
expression [2]. Adhesion signaling via integrins is, therefore, a key contributor to both health and
disease [5–7].
Integrins are normally inactive with low affinity for their endogenous ligands, but they undergo
rapid activation upon various stimuli [8,9]. To convert integrins into active states with different ligand
binding affinities, intracellular signaling (inside-out signaling) is required. As bidirectional receptors,
integrins can also transmit signals back into cells: upon ligand binding in the extracellular domain,
they transmit an outside-in signaling that regulates cell shape, migration, growth, and differentiation.
The ability of integrins to bind and associate with various components of the extracellular
matrix (ECM) or soluble ligands largely depends on the structural conformations of the two subunits
α and β, and distinct conformations are crucial for regulating both inside-out and outside-in cell
signaling [4,10,11].
Concerning the integrin site for ligand binding and from a structural point of view, it is important
to distinguish the two types of α-subunits in integrins: those with or those without an inserted
domain, named the αI domain (Figure 2). In αI-integrins, the αI domain is the binding site for ligands,
whereas in integrins without the αI domain, the ligand-binding site is formed at the interface between
the α-subunit and the β-subunit in its βI domain [11]. Thus, in integrins without an αI domain,
the β subunit contributes to modulate the ligand specificity. The αI and βI domains are structurally
homologous and contain metal ion-dependent adhesion sites (MIDAS) which are able to bind Asp,
Glu, or carboxylic acid residues in ligands. In RGD-binding integrins (without αI), the Arg of RGD
binds the α-subunit while the Asp of RGD coordinates to the Mg2+ ion in the β subunit βI domain
MIDAS. The elucidation of this mode of ligand binding explains the cation dependence of ligand
binding and cell adhesion.
Structural studies (crystallography, nuclear magnetic resonance, NMR, and electron microscopy
studies) have revealed three overall conformational states: a bent, an extended-closed,
and an extended-open conformations (Figure 2); these may correspond to a low affinity conformer,
an activated, and an activated together with ligand-occupied integrin conformers, respectively [12].
However, in some circumstances, the bent form can engage ligands such as fibronectin
fragments [13] or a small molecule that is not a RGD mimetic [14], which do not prime the receptor.
The concept that the extended open integrin conformation corresponds to the conformation with high
affinity for the ligand is well accepted for some integrins, whereas for others there are controversial
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aspects [15]. Binding of extracellular ligands also stabilizes the extended open conformation,
which shows enhanced separation of the integrin intracellular tails that, in turn, transmits signals to the
cytoplasm (outside-in signaling). Because the equilibria of conformational changes and ligand binding
are thermodynamically linked [16], it is reasonable to assume that the extended closed conformer
could have an intermediate affinity for ligands [17].Cancers 2017, 9, 78  3 of 19 
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conformer could have an intermediate affinity for ligands [17]. 
Regulation of integrin affinity by ligands should be viewed as a shifting of the dynamic 
equilibrium between closed, intermediate and open conformers [18]. For many, if not all integrins 
[19], such conformational changes (“activation”) are required to actuate their adhesive function and 
signal transduction [19,20].  
Integrins, like most other cell surface receptors, are heavily glycosylated. The significance of the 
great variation in number of glycosylation sites among integrin subunits is currently unknown. 
Recently, it was reported that N-glycans affect the conformational equilibria of integrins and their 
activation [21]. Moreover, a decrease in the number of N-glycosylation sites on integrin α5β1 stabilizes 
its bent-closed and extended-closed conformations and lowers the ligand binding affinity [22]. 
Integrins form part of a multidimensional system in which complex cellular signaling might be 
influenced by functional cross-talk between the membrane receptors, such as integrins, growth 
factors receptors, cadherins, matrix metalloproteinases (MMPs), etc. It was demonstrated that these 
cross-talk interactions are very important for cell proliferation, invasion, angiogenesis and resistance 
to apoptosis, thus contributing to more aggressive diseases such as cancer [23]. However, the 
understanding of how integrin ligands could activate or inhibit this cross-talking is far from being 
understood.  
Binding of ligands to integrins activates outside-in signaling, which triggers a vast array of 
intracellular signaling events that determine cell fate, as above mentioned. As such, tight regulation 
of signaling via integrins is paramount for normal physiological function, and misregulated integrin 
activity is associated with many pathological conditions including cancer. 
Many studies were devoted to find integrin antagonists, such as antibodies, peptides, and small 
organic molecules, which inhibit integrin function. Preclinical studies suggested that antagonists of 
several integrins might be useful for suppressing tumor angiogenesis and growth either alone, in 
combination or by conjugation with current cancer therapeutics [5,24].  
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Regulation of integrin affinity by ligands should be viewed as a shifting of the dynamic
equilibrium between closed, intermediate and open conformers [18]. For many, if not all integrins [19],
such conformational changes (“activation”) are required to actuate their adhesive function and signal
transduction [19,20].
Integrins, like most other cell surface receptors, are heavily glycosylated. The significance of
the great variation in number of glycosylation sites among integrin subunits is currently unknown.
Recently, it was reported that N-glycans affect the conformational equilibria of integrins and their
activation [21]. Moreover, a decrease in the number of N-glycosylation sites on integrin α5β1 stabilizes
its bent-closed and extended-closed conformations and lowers the ligand binding affinity [22].
Integrins form part of a multidimensional system in which complex cellular signaling might be
influenced by functional cross-talk between the membrane receptors, such as integrins, growth factors
receptors, cadherins, matrix metalloproteinases (MMPs), etc. It was demonstrated that these cross-talk
interactions are very important for cell proliferation, invasion, angiogenesis and resistance to apoptosis,
thus contributing to ore aggressive diseases such as cancer [23]. However, the understanding of how
integrin ligands could activate or inhibit this cross-talking is far from being understood.
Binding of ligands to integrins activates outside-in signaling, which triggers a vast array of
intracellular signaling events that determine cell fate, as above mentioned. As such, tight regulation
of signaling via integrins is paramount for normal physiological function, and misregulated integrin
activity is associated with many pathological conditions including cancer.
Many studies were devoted to find integrin antagonists, such as antibodies, peptides, and small
organic molecules, which inhibit integrin function. Preclinical studies suggested that antagonists of
several integrins might be useful for suppressing tumor angiogenesis and growth either alone, in
combination or by conjugation with current cancer therapeutics [5,24].
Less attention focused on ligands that activate integrins instead of inhibiting them for possible
activation of angiogenesis and tumor growth. However, it was recently recognized that integrin
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agonists could open novel opportunities for therapeutics, which have benefits in increasing rather
than decreasing integrin-dependent adhesion. For instance, a significant factor in chemo-resistance in
melanoma is a loss of integrin-mediated adhesion; in this case, stimulation of integrin signaling by
agonists significantly improved the response to chemotherapy [25].
In this paper, we overviewed the literature about small molecules that directly target integrins
and revealed an activating action on some of them, especially those involved in cancer. These agonist
molecules were examined in terms of structure and behavior from a medicinal chemistry point of view.
2. Agonists or Antagonists: That Is the Question
The complex roles of integrins in several pathologies identify this family of adhesion receptors
as valuable drug targets. To date, most efforts have prompted the development of small molecules
targeting integrins, especially those implicated in cancer (such as αvβ3, αvβ5, α5β1), in platelet
aggregation (αIIβ3), and in the regulation of inflammation and immune functions (such as α4β1, α4β7,
αLβ2 and αMβ2), although to date, no anticancer drug targeting integrins has been approved.
As previously described, integrins can mediate their own functions by changing conformation, as
they exist in a dynamic equilibrium of several conformations that are determined by ligand interaction,
or that induce ligand binding (Figure 2). As classical signaling receptors, following ligand binding,
integrins promote signal transduction processes. Since several reports have shown that different
ligands behave in a dissimilar way, it has been hypothesized that integrin ligand binding could
mediate more than one downstream signaling mechanism [26]. On the basis of this hypothesis,
the binding of different ligands may result in distinct events.
Pharmacologically, ligands can be classified on the basis of their action at the receptor. Agonists are
compounds which bind to receptors and mimic the signaling of endogenous compounds; on the
contrary, antagonists bind to the receptor and block its interaction with endogenous agonists, but do
not induce any receptor activation and signal transduction, and therefore do not possess intrinsic
activity. Additionally, some ligands, defined as partial agonists, possess less ability to activate the
receptor and associated signal transduction, while inverse agonists are compounds that are able to
stabilize the receptor in its inactive conformation. Moreover, a ligand can modulate receptor activity or
binding of agonists/antagonists acting allosterically on a topographically distinct position from the
site of activity or ligand binding: they are defined as allosteric agonists/antagonists.
All these definitions may apply to integrins and integrin-mediated signal transduction, suggesting
that it could be possible to develop small molecules to target specifically a definite integrin
conformation and downstream signaling: a sort of “biased ligand” for integrins [27]. Several studies
suggest that integrins may share this feature with G-protein coupled receptors (GPCRs) for which
“biased agonism” or differential signaling has been a deeply studied phenomenon over the last
10 years [28]. However, further investigations will be necessary to deepen our knowledge on these
processes in integrin functions.
Recently, several studies have reported the development of small molecules acting as integrin
agonists, that may display potential clinical applications. Analyzing those ligands, it has been
recognized that not all agonists behave in the same manner, supporting the idea of biased agonism
for integrins.
Integrin activation and signal transduction may be differently modulated by different integrin
agonists (Figure 3). Faridi and coworkers reported that small molecule agonists for the αMβ2
integrin induce modest and local changes in integrin structure, while the binding of activating
antibodies, which activate integrins or that bind in an activation-sensitive manner, prompt more
global conformational changes, inducing outside-in signaling [29].
These new insights into integrin functions require a better characterization of synthetic
compounds (both agonists and antagonists): it is crucial to investigate deeply their effects on several
functions mediated by integrins such as cell adhesion, intracellular signaling and integrin trafficking.
Furthermore, integrin internalization regulates several processes, like cell migration and adhesion,
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and is relevant in many pathological conditions, especially in cancer [30,31]. It would be interesting also
to investigate the effects of integrin agonists and antagonists also on integrin trafficking: for example,
these data could be useful to develop small molecules able to deliver selectively cytotoxic molecules
into cancer cells. It is currently unclear whether integrin agonists and antagonists may mediate
internalization in a different way.Cancers 2017, 9, 78  5 of 19 
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context, Cilengitide has been reported to be a potent inhibitor of angiogenesis able to induce 
apoptosis of growing endothelial cells via the inhibition of the interaction between integrins with 
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Despite great expectations, antagonists of αvβ3 and αvβ5 integrin that have entered clinical trials 
as antiangiogenic agents for cancer treatment have generally been unsuccessful. In phase III studies, 
the addition of Cilengitide to temozolomide chemo-radiotherapy failed to be effective and therefore, 
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3. RGD-Bindi g Integrin Agonists
Cilengitide, the cyclic RGD pentapeptide c(-RGDf(NMe)V-), is a potent integrin antagonist
targeting the integrins αvβ3, αvβ5 and α5β1, developed for treatment of glioblastomas and other
tumors (Compound 1, Figure 4) [32]. Its features and potency boosted research in the last two decades
towards a plethora of new small molecules able to antagonize integrins [33–35]. The inhibition
of integrin-ligand interactions suppresses cellular growth and induces apoptotic cell death, and in
this context, Cilengitide has been reported to be a potent inhibitor of angiogenesis able to induce
apoptosis of growing endothelial cells via the inhibition of the interaction between integrins with their
ECM ligands.
Despite great expectations, antagonists of αvβ3 and αvβ5 integrin that have entered clinical
trials as antiangiogenic agents for cancer treatment have generally been unsuccessful. In phase III
studies, the addition of Cilengitide to temozolomide chemo-radiotherapy failed to be effective and
therefore, Cilengitide will not be further developed as an anticancer drug. Nevertheless, integrins
remain a potential treatment target for glioblastomas [36].
The full concept of exploiting integrin antagonism as an antiangiogenic therapy was criticized
in 2009, in a study [37] reporting that low-dose treatment with RGD-mimetic integrin antagonists
may paradoxically enhance angiogenesis and tumor growth. This behavior has been ascribed to
in vivo evidence that low (nanomolar) concentrations of RGD-mimetic αvβ3 and αvβ5 antagonists can
paradoxically stimulate tumor growth and tumor angiogenesis. Yet in 2001, Legler and coworkers
confirmed that cyclic RGD-peptide (cRGD) acted as an antagonist on αvβ3 at high concentrations,
and as agonist at low concentrations [38]. Even if the Cilengitide concentrations used in clinical trials
far exceeded the described “pro-angiogenic” concentrations, and therefore the adverse biological
effect should not be expected, these findings suggest that nanomolar plasma concentrations of those
compounds with ambivalent behavior should be avoided, or that their delivery should be redesigned.
The ambivalent behavior of Cilengitide prompts the need for better understanding of how binding
events modulate integrin activity, and the role of a ligand as an agonist or an antagonist with the
perspective of designing new compounds that are unable to promote integrin activation, and thus
can act as pure antagonists or vice versa as pure agonist for internalization studies and drug delivery.
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In a recent molecular dynamic (MD) study [39], authors analyzed the multidomain receptor of αvβ3
integrin in complexes with two forms of fibronectin, wild type (wtFN10) and mutated high affinity
(hFN10), which act, respectively, as an agonist activating the receptor, or as a true antagonist inhibiting
the receptor. Interaction hotspots were identified in the integrin binding site that specifically respond
to the fibronectin sequence variations and allosterically drive conformational changes towards integrin
activation or inhibition. They speculated that antagonism is determined by the presence of bulky
moieties, i.e., aromatic, flanking RGD that optimally pack in the integrin recognition site. Agonism is
favored by the absence of such flanking motifs, which allows more conformational freedom and pushes
integrin towards the active conformation.Cancers 2017, 9, 78  6 of 19 
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squaramide molecules that exhibited higher potency at inhibiting mammalian cell adhesion than 
RGD tripeptides in culture medium inhibition tests. But compound 3 (Figure 4), when immobilized 
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Other molecules displaying agonist or ambivalent behavior towards RGD binding integrins
have also been reported. Aizpurua and coworkers [40], designed and synthesized RGD cyclic
peptidomimetics incorporating an α-amino-β-lactam scaffold. The antagonist affinities against αvβ3
integrin on human endothelial cells (HUVECs) by means of adhesion inhibition assays resulted in
comparable values to that of Cilengitide. On the contrary, gene expression microarray assays on
angiogenesis-related gene regulation of DNA samples extracted from HUVECs after treatment with
the RGD, in case of β-lactam ligand 2 (Figure 4), gave opposite behaviors with respect to Cilengitide,
suggesting an in vivo proangiogenic effect by the compound which might act as an agonist ligand of
the RGD receptor.
Once again in the field of mimics of the natural RGD sequence, Luk [41] reported on a class of
squaramide molecules that exhibited higher potency at inhibiting mammalian cell adhesion than RGD
tripeptides in culture medium inhibition tests. But compound 3 (Figure 4), when immobilized on
a bio-inert surface resistant to non-specific cell adhesion, facilitated a faster (1.4 times) and stronger
focal adhesion than linear RGD ligands, suggesting that 3 could induce more adhesion points within
an adhered cell, and thus should be considered as an agonist for integrin rather than antagonist.
The ability to increase cell adhesion when immobilized on inert surfaces has also been demonstrated
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by some RDG peptides [42] and by small molecules. Mas-Moruno [43] studied the immobilization of
integrin-binding peptidomimetics (compounds 4 and 5, Figure 4) on titanium (Ti) as a feasible and
powerful strategy to mimic a bone extracellular matrix, and thus to improve osteoblast adhesion and
accelerate osseointegration of implants. Compounds 4 and 5 are αvβ3 and α5β1 selective agonists,
respectively, and both fostered adhesion and spreading of SaOS-2 cells on Ti, thus opening promising
prospects for diverse clinical applications of agonists in dentistry and orthopedics.
Recently, a novel series of β-lactam derivatives designed and synthesized to target RGD-binding
and leukocyte integrins, was reported (Figure 5) [44,45]. The molecules contain an azetidinone ring as
a rigid cyclic central core, with two arms holding a carboxylic acid and a basic moiety, as in the RGD
sequence, or a carboxylic acid side chain coupled with a 4([(N-2-methylphenyl)ureido]-phenyl acetyl
motif (PUPA) [46] on the β-lactam nitrogen atom. These new ligands were evaluated by investigating
the effects on integrin-mediated cell adhesion and cell signaling in cell lines expressing αvβ3, αvβ5,
αvβ6, α5β1, αIIbβ3, α4β1, and αLβ2 integrins, and in solid phase binding assays. Interestingly, several
of these derivatives were found to be good antagonists, and by modulating the basicity and the length
of the side chains, selective and potent agonists were also found. In particular, several compounds
could induce cell adhesion and promote cell signaling mediated by αvβ3, αvβ5, and α5β1 integrins.
The more potent β-lactam-based agonists are depicted in Figure 5, where the selected molecules showed
EC50 values ranging from 1 to 100 nM. In particular, β-lactams 8–12 showed higher and sometimes
selective affinity toward α5β1 integrin, whereas β-lactam 6 and 8 showed affinity toward integrin αvβ3.
Compound 7 with an acidic terminus of β-alanine and an ureido PUPA motif behaved as an antagonist
toward the αvβ3 integrin at low concentrations, and as an agonist at higher concentrations, thus
mimicking the concentration-dependent behavior of Cilengitide, but with an opposite trend. It was
demonstrated that cell adhesion mediated by the new β-lactam agonists effectively and specifically
involved α5β1, αvβ3, and α4β1 integrins, respectively. Regarding αvβ3 integrin, adhesion of melanoma
cells was increased in a concentration related-manner by compounds 6 and 8, as well as by fibronectin.
Moreover, pre-incubation with a cyclic RGD mimetic c(-RGDfV-), a well-known antagonist of RGD
integrins, significantly reduced melanoma cell adhesion mediated by compounds 6 and 8, thus
suggesting that both β-lactam molecules may bind to the MIDAS site as c(-RGDfV-). The same
experiment on α5β1 expressing cells, showed reduction of cell adhesion mediated by azetidinones 9
and 12 but not by 10 and 11, suggesting that β-lactams 9 and 12 may bind the MIDAS site, whereas
10 and 11 might bind to an allosteric site. Pre-incubation with a neutralizing antibody against the α5
or αv subunits blocked the augmented adhesion induced by all β-lactam agonists 6 and 8–12, thus
inducing the hypothesis that compounds 10 and 11 could bind to allosteric sites specifically located on
α subunits.
Starting from the hypothesis that a loss of integrin-mediated adhesion is a significant causative
factor in chemo-resistance in melanoma cells, it has been shown that integrin agonists can act as
adjuvants in chemotherapy [25]. Disintegrins are a group of integrin-binding proteins found in snake
venoms. Contortrostatin is a disintegrin possessing two RGD motifs that, on binding to αv and
α5β1 integrins usually present on cell surface of melanoma cells, is able to inhibit cell adhesion and
platelet aggregation, but to activate integrin-mediated signaling. In an in vivo model, the combined
treatment of contortrostatin with araC (Cytarabine, a chemotherapy drug) significantly decreased
tumor growth, probably due to the ability of contortrostatin to stimulate integrin-mediated signaling,
leading to a significantly improved response to chemotherapy. These data suggest that combining
chemotherapy with integrin agonists may be promising for improving therapeutic outcomes in patients
with metastatic melanoma [25].
Several years ago it was discovered that integrins can interact and colocalize with MMP2 on the
surface of angiogenic blood vessels in vivo [47]. The binding of αvβ3 integrin to MMP2 on the cell
surface is fundamental for the exploitation of this enzyme on the cell surface of invasive endothelial
cells. Therefore, the development of new ligands, binding to αvβ3 integrin and as a consequence
disrupting MMP2-αvβ3 integrin interaction would be interesting for anti-angiogenic therapy in cancer.
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Silletti et al. reported some integrin ligands [48,49] which did not bind to the RGD binding site of
αvβ3 integrin, did not alter MMP2 catalytic activity directly, and did not interfere with the binding
of αvβ3 integrin to the ECM endogenous ligand vitronectin. Moreover, these compounds inhibited
tumor cell capacity to use MMP2 to degrade ECM by disrupting the integrin-MMP2 protein interaction.
In in vivo models, the best candidate, compound 13 (TSRI265, Figure 6) showed potent antiangiogenic
activity and inhibited tumor growth [49].
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4. Leukocyte Integrins
The mutual relationship between inflammation and cancer is nowadays well established,
and immunomodulation is considered a useful tool not only for the treatment of inflammatory
pathologies and autoimmune diseases, but also in cancer therapy [50,51]. hen the release of
chemokines and growth factors due to inflammation is chronic, oxidative damage and DNA mutations
may occur, thus supporting tumor development [52]. On the other hand, the effects of cancer on the
immune system include several pathways such as the up-regulation of immune-suppressive cytokines,
and the dysregulation of T-cell mediated host responses. In this context, the role of adhesion molecules
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is fundamental for leukocyte recruitment and migration and for T-cell infiltration in tumor tissues.
Moreover, regulation of the expression and activity of specific adhesion molecules has a strong impact
on B-cell homing, survival and environment mediated drug resistance in malignancies such as non
Hodgkins lymphoma (B-NHL) [53,54]. An important aspect is the binding-detachment ratio that
controls cell movement and is responsible for the dynamic aspects of the process. Recent studies have
shown that fast leukocyte recruitment to the site of injury occurs during acute inflammation, while
slower processes may be observed for the immune response in pancreatic and hepatic cancer [55].
In this complex scenario, modulation of integrin activity plays a fundamental role. While antagonists
may interfere in leukocyte primary functions, agonists may induce a stronger adhesion that, avoiding
detachment, prevents normal cell migration processes [56]. Leukocytes express on their surface,
selected classes of integrins (see Figure 1), and, among them, αLβ2 (LFA-1, CD11a/CD18), αMβ2
(CD11b/CD18, Mac-1), α4β7 (LPAM) and α4β1 (VLA-4) received major attention as targets for small
molecule ligand-induced immunomodulation.
4.1. β2 Integrin Agonists
Like other integrins, those belonging to the β2-family possess the αI-domain as the main
ligand-binding site in the α subunit, as mentioned above. This domain is a 190–200 residue fragment
at the N-terminus of the α chain, with seven α helices surrounding a mostly parallel β sheet,
which contains a MIDAS. A similar domain, named the I-like domain, is present also in the β2 subunit.
The crystal structure of αL (CD11a) and αM (CD11b) I domains allowed two different conformations
to be identified [57,58]: a low-affinity quaternary state (closed-inactive) and a high-affinity state
(open-active). When ligand-induced activation occurs, a β2 I-like domain rearrangement activates the
αI domain [59]. Reported antagonists usually stabilize the low-affinity confirmation of I domain and
allosterically inhibit ligand binding (αI allosteric antagonists). Other known antagonists bind to the
I-like domain in the α-unit, activating this portion of the receptor but blocking the activation of the
α-unit (α/β I allosteric antagonists) [57].
The idea that activation instead of inhibition of leukocyte integrins may represent a useful
approach for inflammatory disease treatment is supported by the finding that induction of a persistent
active state may lead to the loss of integrin mediated functionality [60]. Initially, small molecule
agonists of β2 integrins have been identified starting from the DDGW peptide that mimics the binding
sequence of matrix metalloproteinases (proMMP)-2 and -9 to these receptors. Via a high-throughput
phage display screening, a small library of 2-thioxothiazolidin-4-one derivatives was selected for their
specific binding affinity to the αM and αL I domains. Compound 14, IMB-10 (Figure 7), inhibited
competitive antibody binding and showed an interesting ability to increase binding of αMβ2 integrin
to matrix metalloproteinases and fibrinogen (EC50 = 0.4 ± 0.2 µM) [61]. Docking studies suggested
the presence of a hydrophobic cavity able to host IMB-10 close to the C-terminal helix in the open
form of the αM subunit. In the closed inactive form, this cavity is not available, since it is occupied by
some residues of the C-terminal helix. The phenylbutadienyl chain of IMB-10 fits to the bottom of the
pocket, while the 2-methylphenyl group establishes aromatic stacking with a phenylalanine residue
of the receptor. A further hydrogen bond occurs between the carbonyl group of the heterocyclic core
and a serine hydroxyl function. A similar pocket is present also in the αL subunit, but the calculated
fitting was less effective. This interaction between IMB-10 and the αM I domain strongly stabilizes the
open active form of the receptor, preventing the switch back to the closed inactive form, where the
pocket needs to be empty to allocate the C-terminal helix. Additional experiments also showed that
IMB-10 is able to block αMβ2-mediated cell migration in vitro and leukocyte recruitment in vivo; thus,
confirming the potential of this small molecule as an anti-inflammatory lead compound. Furthermore,
this compound displayed anticancer activity in in vivo models [56]. Interestingly, IMB-10 reduced
leukocyte infiltration in tumors and altered the invasion ability of cancer cells, probably blocking
integrin-mediated inflammatory cell recruitment. Therefore, IMB-10 could be a promising lead for the
development of therapies to fight leukocyte-originating malignancies.
Cancers 2017, 9, 78 10 of 18
Cancers 2017, 9, 78  10 of 19 
 
suggested the presence of a hydrophobic cavity able to host IMB-10 close to the C-terminal helix in 
the open form of the αM subunit. In the closed inactive form, this cavity is not available, since it is 
occupied by some residues of the C-terminal helix. The phenylbutadienyl chain of IMB-10 fits to the 
bottom of the pocket, while the 2-methylphenyl group establishes aromatic stacking with a 
phenylalanine residue of the receptor. A further hydrogen bond occurs between the carbonyl group 
of the heterocyclic core and a serine hydroxyl function. A similar pocket is present also in the αL 
subunit, but the calculated fitting was less effective. This interaction between IMB-10 and the αM I 
domain strongly stabilizes the open active form of the receptor, preventing the switch back to the 
closed inactive form, where the pocket needs to be empty to allocate the C-terminal helix. Additional 
experiments also showed that IMB-10 is able to block αMβ2-mediated cell migration in vitro and 
leukocyte recruitment in vivo; thus, confirming the potential of this small molecule as an anti-
inflammatory lead compound. Furthermore, this compound displayed anticancer activity in in vivo 
models [56]. Interestingly, IMB-10 reduced leukocyte infiltration in tumors and altered the invasion 
ability of cancer cells, probably blocking integrin-mediated inflammatory cell recruitment. Therefore, 
IMB-10 could be a promising lead for the development of therapies to fight leukocyte-originating 
malignancies. 
 
Figure 7. β2 integrin agonists; data are expressed as EC50 (mean±SD, nM) vs. ligand employed in cell 
adhesion assay. 
A screening of >13,500 compounds via a no-wash cell adhesion-based high throughput assay 
[62], allowed the identification of a novel family of compounds able to increase adhesion to the 
fibrinogen of human erythroleukemia cells, transfected with αMβ2 integrin. The common motif of 
these compounds’ backbone is the presence of the 2-thioxothiazolidin-4-one heterocyclic core, as in 
IMB-10. By merging information obtained from structure-activity relationship study and in-silico 
docking experiments, the interaction of these agonists with the hydrophobic pocket between the α7 
Figure 7. 2 integrin agonists; data are expressed as E 50 ( ean SD, n ) vs. ligand e ployed in cell
a hesion assay.
A screening of >13,500 compounds via a no-wash cell adhesion-based high throughput assay [62],
allowed the identification of a novel family of compounds able to increase adhesion to the fibrinogen of
human erythroleukemia cells, transfected with αMβ2 integrin. The common motif of these compounds’
backbone is the presence of the 2-thioxothiazolidin-4-one heterocyclic core, as in IMB-10. By merging
information obtained from structure-activity relationship study and in-silico docking experiments,
the interaction of these agonists with the hydrophobic pocket between the α7 and α1 helixes of I domain
was confirmed [63]. In particular, compound 15 (Figure 7), possessing a planar conjugated furanyl
aromatic chain, best fits into the cavity, orienting the carbonyl oxygen toward serine and threonine
residues able to establish stabilizing hydrogen bonds. Further development of this class of compounds,
named leukadherins, allowed the identification of three ligands with excellent activity in vitro
(Leukhaderin-1 LA1, Leukhaderin-2 LA2 and Leukhaderin-3 LA3, compounds 14–16, Figure 7) [64].
Among them, LA-1 (compound 16) was selected as the lead compound, increasing the αMβ2 integrin
mediated adhesion to fibrinogen with an EC50 value of 4 µM. Further experiments confirmed that
LA-1 binds to the αI domain in the high affinity conformation through allosteric stabilization of the
αI in the open active form. Moreover, leukadherins reduce leukocyte trans-endothelial migration
in vitro and decrease recruitment and extravasation in vivo. However, they did not behave as ligand
mimics, since receptor clustering and outside-in signaling did not occur upon binding to the receptors.
Comparison of the function of leukhaderins as agonists to antibodies suggests that these small molecule
ligands are able to induce conformational changes limited to the αI domain, which is not sufficient
to activate intracellular signaling via the complex cytoskeleton protein machinery. On the contrary,
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binding of agonist antibodies mimics the natural ligand and induces extension of the heterodimer with
a global conformational rearrangement. This activation produces outside-in signaling, but sometimes
leads to adverse effects [29]. An insight on LA-1 binding effects was performed with atomic force
microscopy (AFM)-based single-cell force spectroscopy (SCFS), by comparing the biomechanical
effects of leukadherin-specific ligands with those induced by Mn2+, a specific integrin agonist [65].
These investigations revealed the existence of two distinct populations of receptors: one with a strong
linkage to the cytoskeleton and which is activated by interaction with Mn2+, the other with weaker
connections that are broken when leukadherin binding occurs, inducing formation of membrane
tether bonds. Thus, LA-1 binding leads to conversion of the closed inactive form of the receptor to
an intermediate affinity conformation, different from the open-active form induced by other classes
of agonists (Figure 2). This novel mode of action did not show significant side effects so far, thus
prompting novel in vivo studies on inflammatory disease animal models [66,67].
A different mechanism of activation occurs for compound 17 (Figure 7) [68], a small
molecule sharing structural similarities with α/β I allosteric antagonists studied by Genentech and
Hoffmann-Laroche [69]. This αLβ2 ligand displayed agonist activity in the presence of physiologic
divalent cations as Ca2+ and Mg2+, but behaved as an adhesion inhibitor in the presence of Mn2+.
This unusual behavior was confirmed in several different assays as binding tests, static cell adhesion
and flow chamber assays, both with human erythroleukemia cells transfectants expressing αLβ2 and
physiologic leukocytes. The proposed hypothesis is that cations may bind to an adjacent MIDAS
(ADMIDAS), generating complexes that are slightly different depending on the metal. For Ca2+ and
Mg2+, the complex between compound 17 and the β I-like domain can bind to αL I domain, inducing
a switch to the open active conformation. Recently, XVA143 (compound 18, Figure 7), a α/β I allosteric
antagonist, having structural similarities to compound 17, was reported to induce a semi-active form
of αLβ2. This conformation induces “rolling adhesion” as the beginning of leucocytes recruitment, but
does not mediate intracellular signaling and promotes an altered internalization/recycling behavior.
The splitting of different down-stream effects depending on the binding site and on epitope formation
suggests that much is still to be understood [70].
Based on SAR information obtained from on-bead screens of tagged one-bead one-compound
combinatorial libraries, a novel αLβ2 ligand acting as agonist was identified [71]. The small molecule
19, named IBE-667 (Figure 7), increased the binding of biotinylated soluble ICAM-1 to activated T-cells,
thus acting as an ICAM-1 binding enhancer for LFA-1. Co-crystallization experiments revealed that
IBE-667 does not bind to the MIDAS site of LFA-1 but instead to a pocket usually preferred by allosteric
antagonists such as Lovastatin (αL domain).
4.2. α4β1 Integrin Agonists
The α4β1 integrin is a key player in the homing of progenitor cells to inflammation sites and
mediates cell adhesion to VCAM-1 and to the alternatively spliced segment-1 (CS1) of fibronectin.
This receptor lacks an I domain, and ligand binding occurs at the interface between α and β subunits,
through coordination to a MIDAS in the α subunit. Crystal structure of α4β1 integrin is still not
available, and all the designed ligands have been planned based on the structure of α4β7 integrin that
shares the same α subunit [72].
As reported above [60], potential application of integrin agonists as therapeutic agents started
after the observation that freezing the α4β1 integrin (VLA-4) in a high-avidity state by activation with
monoclonal antibodies generated a strong interference with trans-endothelial migration of leukocytes.
Although this study suggested a novel approach to prevent rapid tissue invasion by VLA-4-positive
cells during inflammation, α4β1 integrin agonists have been poorly explored in comparison with
antagonists. The first agonist THI0019 (compound 20, Figure 8) was synthesized using a potent
antagonist as template, by introducing a methyl ester instead of a carboxylic function, thus avoiding
MIDAS affinity [73]. Cell adhesion assays with T lymphocyte cells in the presence of VCAM-1 showed
an enhancement of cell binding with an EC50 of 1.2 µM; comparable agonist activity was also observed
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toward α4β7, α5β1 and αLβ2 integrins, while negligible effects were observed on αvβ3, α1β1 and
α2β1 integrins. Further bioassays, supported by docking experiments based on the α4β7 crystal
structure, suggested that THI0019 temporarily occupies the ligand binding pocket, bridging both α
and β subunits and inducing a small conformational change in the β unit that favors ligand binding
and agonist displacement, in agreement with the binding mode of other small-molecule integrin
systems [72,74]. Different from previously described β2 integrin agonists, THI0019 is a full agonist and
promotes rolling, migration and cell homing, and, in this case, the up-regulation of integrin activity
should be useful for cell retention in stem cell therapy. In fact, in patients who have had a myocardial
infarction, early retention of transplanted stem cells may significantly improve heart functions [75,76].
Co-administration of stem cells with a α4β1 integrin agonist such as THI0019 may potentially improve
cell retention at the site of injury, and in this way enhance stem cell therapy.
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was found to be a selective agonist of α4β1 integrin, having an EC50 of 12.9 nM in T lymphocyte cell 
adhesion assays to VCAM-1, and activating outside-in signaling, evaluated quantifying ERK1/2 
phosphorylation. The binding mode of the lactam was further explored by using a conformation-
specific anti-β1 integrin antibody (HUTS-21) able to recognize a ligand-induced binding site (LIBS) 
epitope that is exposed upon agonist binding or partial integrin activation. Agonist 21 significantly 
increased HUTS-21 antibody binding in a concentration-dependent manner, thus demonstrating the 
induction of a conformational rearrangement in the β1 subunit that resulted in exposure of the HUTS-
21 epitope and a more active conformation. 
5. Laminin-Binding Integrins 
Engagement of laminins by a group of integrin family proteins, including integrins α3β1, α6β1, 
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The switch from antagonist to agonist behaviour, due to small changes in the molecule backbone,
was also recently reported for β-lactam ligands, designed to target RGD-binding and leukocyte
integrins [45]. A library of small molecules was indeed synthesized and screened for the affinity and
selectivity to different classes of integrins. Within this study, compound 21 (Figure 8) was found to be
a selective agonist of α4β1 integrin, having an EC50 of 12.9 nM in T lymphocyte cell adhesion assays
to VCAM-1, and activating outside-in signaling, evaluated quantifying ERK1/2 phosphorylation.
The binding mode of the lactam was further explored by using a conformation-specific anti-β1
integrin antibody (HUTS-21) able to recognize a ligand-induced binding site (LIBS) epitope that
is exposed upon agonist binding or partial integrin activation. Agonist 21 significantly increased
HUTS-21 antibody binding in a concentration-dependent manner, thus demonstrating the induction of
a conformational rearrangement in the β1 subunit that resulted in exposure of the HUTS-21 epitope
and a more active conformation.
5. Laminin-Binding Integrins
Engagement of laminins by a group of integrin family proteins, including integrins α3β1,
α6β1, α7β1 and α6β4, is an important event in the interaction of cells with basement membranes.
Different isoforms of both integrins and laminins showed specific affinities in binding studies, thus
inducing different effects in cell physiology [77]. Laminin-binding integrins have been suggested to be
potent mediators of tumor cell motility, migration and invasion during metastasis but, depending on
the conditions, they may have pro-metastatic or anti-metastatic functions [78].
Within this class of receptors, integrin α3β1 [79] is highly expressed in podocytes, terminally
differentiated visceral epithelial cells, and primarily binds to laminin expressed in the glomerular
basement membrane (GBM). Integrin α3β1 mediates stable adhesion and maintains the integrity of
podocytes and the glomerular filtration barrier. Damages or protein mutations that reduce either
integrin activation or expression, may result in podocyte alteration and may cause proteinuria.
The small molecule pyrintegrin (Figure 9) behaves as an activating/protecting agent of integrins
from puromycin aminonucleoside (PAN)-induced damage, via a dose-dependent effect on the
podocytes (EC50 = 0.8 µM) [80]. Moreover, pyrintegrin showed a strong survival-promoting effect on
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dissociated human embryotic stem cells (hESCs), inducing in a few hours a dramatic increase in the
adhesion to laminin-coated plates. Further experiments confirmed that pyrintegrin increases integrin
activity and activates intracellular signaling [81]. This molecule was also capable of promoting adipose
tissue formation from either transplanted human adipose stem/progenitor cells or host endogenous
cells, both in vitro and in vivo. The efficacy in endogenous adipogenesis without cell transplantation
suggest that pyrintegrin treatment may be also exploited as an alternative to autologous fat transfer in
post-operative volume reduction [82].
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6. Collagen-Binding Integrins 
Under disease conditions, such as inflammation, tissue regeneration events, and tumors, 
collagen-binding integrins α1β1, α2β1, α10β1, and α11β1 play a more-prominent role. Integrins α1β1 and 
α2β1 might be needed for a correct and innate immune response in various populations of immune 
cells, whereas α10β1 and α11β1 appear to be central to how connective tissue cells perform in the 
musculoskeletal system [83]. 
Examples of small molecules that act as agonists of collagen-binding integrins are very poor. 
Chung et al. reported on the effect of some snake venom toxins such as the C-type lectin protein 
Aggretin, which induces vascular smooth muscle cell proliferation and migration, and stimulates the 
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6. Collagen-Binding Integrins
Under disease conditions, such as inflammation, tissue regeneration events, and tumors,
collagen-binding integrins α1β1, α2β1, α10β1, and α11β1 play a more-prominent role. Integrins α1β1
and α2β1 might be needed for a correct and innate immune response in various populations of immune
cells, whereas α10β1 and α11β1 appear to be central to how connective tissue cells perform in the
musculoskeletal system [83].
Examples of small molecules that act as agonists of collagen-binding integrins are very poor.
Chung et al. reported on the effect of some snake venom toxins such as the C-type lectin protein
Aggretin, which induces vascular smooth muscle cell proliferation and migration, and stimulates the
signaling pathways via activation of α2β1 [84]. However, a recent contribution by the same authors
reported that a small mass peptide fragment of aggretin may bind integrin α2β1 and acts as antagonists
of angiogenesis, thus reversing the behavior compared to aggretin [85].
7. o cl sio s
I te ri s are cr cial tra s e ra e rece t rs, se acti e is ite c lex a t et
c letel erst . I tegrins i terc ect extracell lar a i tracell lar c art e ts, t s
acti as a i irecti al tra s itti tsi e-i r i si e- t cell lar si als.
It as ascertai e t at acti ati f i te ri s cc rs ia c f r ati al rearra e e t fr
be t-close a o e -acti e states i t e extracell lar o ai . cti atio state of i tegri s e e s
o binding to specific ligands, and it is important to point out that the strength of this binding (affinity)
could be modulated by various factors, including the status of glycosylation of integrin, as recently
reported [21,22].
ess attention has been evote to agonist ligan s that activate integrins. Integrin agonists co l
o en novel op ortunities for therapeutics, which gain benefits to increase rather than decrease integrin
activities, such as adhesion. As an example, it was reported that the activation of integrin β1 attenuates
invasion by stabilizing adhesions high integrin activation in a 3D matrix [86].
Although the potential therapeutic application of integrin agonists exists, it is important to
ascertain the exact behavior of new integrin ligands (antagonist or agonist) towards several cellular
events mediated by integrins, such as adhesion, signaling, clustering, and trafficking. In case of
an ambivalent role (antagonist and agonist together) it would be extremely important to determine if
this is concentration-dependent, such as the case of Cilengitide. Appropriate knowledge of this aspect
should limit possible failures at a late stage of clinical trials of future lead compound.
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Given the key role exploited by integrins in cancer, it would be important to deepen our knowledge
in this field. In particular, integrin agonists have to date been studied only as chemotherapy adjuvants
in melanoma tumor [25], therefore, it would be useful to better understand which therapeutic role
integrin agonists could have in cancer, and in different tumor models, but extreme caution must be
taken after the case of Cilengitide.
Moreover, it is important to establish if an integrin agonist behaves as an allosteric ligand.
An allosteric ligand could have the advantage of the ability to prime the integrin on leaving the
main binding site free, thus allowing processes such as integrin clustering or other interactions with
cytokines to occur, as reported for allosteric agonist antibodies of β1 integrins, which activate cytokine
TGF-β in melanoma. This mechanism results in stromal activation, neo-angiogenesis and an increase
in the number of T lymphocytes within the tumor microenvironment, which attentuated tumor growth
and conferred long-term survival benefit [87].
Another important point to be addressed is the effect of ligands (agonists and antagonists)
on integrin trafficking and internalization, because these processes regulate several events such as
cell migration and adhesion, and are relevant in many pathological conditions, especially in cancer.
Investigations on integrin internalization could be useful to exploit small molecules such as drug
cargoes, which able to selectively bind and activate integrins, and to deliver cytotoxic molecules
into cancer cells via integrin endocytosis. Now, it is currently unclear whether integrin agonists and
antagonists mediate internalization in a different way.
The realization that different ligands can activate or inhibit integrins in a dissimilar way and
that “biased agonism” could be applied also to integrins, suggests that it should be possible to
design synthetic agents that specifically target an integrin-mediated effect. Therefore, a better and
complete characterization of small molecules that behave as integrin agonists or antagonists will be
paramount for the development of novel drugs that target integrins with high potential and reduced
adverse effects.
Acknowledgments: Authors thank Santi Spampinato for fruitful discussions and for reading the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Humphries, M.J. Integrin structure. Biochem. Soc. Trans. 2000, 28, 311–339. [CrossRef] [PubMed]
2. Hynes, R.O. Integrins: Bidirectional, allosteric signalling machines. Cell 2002, 110, 673–687. [CrossRef]
3. Humphries, J.D.; Byron, A.; Humphries, M.J. Integrin ligands at a glance. J. Cell Sci. 2006, 119, 3901–3903.
[CrossRef] [PubMed]
4. Campbell, I.D.; Humphries, M.J. Integrin Structure, Activation, and Interactions. Cold Spring Harb.
Perspect. Biol. 2011, 3, a004994. [CrossRef] [PubMed]
5. Ley, K.; Rivera-Nieves, J.; Sandborn, W.J.; Shattil, S. Integrin-based Therapeutics: Biological Basis, Clinical Use
and New Drugs. Nat. Rev. Drug Discov. 2016, 15, 173–183. [CrossRef] [PubMed]
6. Goodman, S.L.; Picard, M. Integrins as therapeutic targets. Trends Pharmacol. Sci. 2012, 33, 405–412. [CrossRef]
[PubMed]
7. Winograd-Katz, S.E.; Fassler, R.; Geiger, B.; Legate, K.R. The integrin adhesome: From genes and proteins to
human disease. Nat. Rev. Mol. Cell Biol. 2014, 15, 273–288. [CrossRef] [PubMed]
8. Kim, C.; Ye, F.; Ginsberg, M.H. Regulation of integrin activation. Annu. Rev. Cell Dev. Bi. 2011, 27, 321–345.
[CrossRef] [PubMed]
9. Shattil, S.J.; Kim, C.; Ginsberg, M.H. The final steps of integrin activation: The end game. Nat. Rev. Mol.
Cell Biol. 2010, 11, 288–300. [CrossRef] [PubMed]
10. Luo, B.-H.; Carman, C.V.; Springer, T.A. Structural basis of integrin regulation and signaling.
Annu. Rev. Immunol. 2007, 25, 619–647. [CrossRef] [PubMed]
11. Springer, T.A.; Dustin, M.L. Integrin inside-out signaling and the immunological synapse. Curr. Opin.
Cell Biol. 2012, 24, 107–115. [CrossRef] [PubMed]
Cancers 2017, 9, 78 15 of 18
12. Beglova, N.; Blacklow, S.C.; Takagi, J.; Springer, T.A. Cysteine-rich module structure reveals a fulcrum for
integrin rearrangement upon activation. Nat. Struct. Biol. 2002, 9, 282–287. [CrossRef] [PubMed]
13. Adair, B.D.; Xiong, J.-P.; Maddock, C.; Goodman, S.L.; Arnaout, M.A.; Yeager, M. Three-dimensional EM
structure of the ectodomain of integrin αvβ3 in a complex with fibronectin. J. Cell Biol. 2005, 168, 1109–1118.
[CrossRef] [PubMed]
14. Zhu, J.; Zhu, J.; Negri, A.; Provasi, D.; Filizola, M.; Coller, B.S.; Springer, T.A. Closed headpiece of integrin
αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening. Blood 2010, 116,
5050–5059. [CrossRef] [PubMed]
15. Zhu, J.; Zhu, J.; Springer, T.A. Complete integrin headpiece opening in eight steps. J. Cell Biol. 2013, 201,
1053–1068. [CrossRef] [PubMed]
16. Marvin, J.S.; Hellinga, H.W. Manipulation of ligand binding affinity by exploitation of conformational
coupling. Nat. Struct. Biol. 2001, 8, 795–798. [CrossRef] [PubMed]
17. Takagi, J.; Petre, B.M.; Walz, T.; Springer, T.A. Global conformational rearrangements in integrin extracellular
domains in outside-in and inside-out signaling. Cell 2002, 110, 599–611. [CrossRef]
18. Luo, B.H.; Springer, T.A. Integrin structures and conformational signaling. Curr. Opin. Cell Biol. 2006, 18,
579–586. [CrossRef] [PubMed]
19. Yednock, T.A.; Cannon, C.; Vandevert, C.; Goldbach, E.G.; Shaw, G.; Ellis, D.K.; Liaw, C.; Fritz, L.C.;
Tanner, L.I. α4β1 Integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is
conformationally responsive to ligand. J. Biol. Chem. 1995, 270, 28740–28750. [CrossRef] [PubMed]
20. Bazzoni, G.; Hemler, M.E. Are changes in integrin affinity and conformation overemphasized?
Trends Biochem. Sci. 1998, 23, 30–34. [CrossRef]
21. Hou, S.; Hang, Q.; Isaji, T.; Lu, J.; Fukuda, T.; Gu, J. Importance of membrane-proximal N-glycosylation on
integrin b1 in its activation and complex formation. FASEB J. 2016, 30, 4120–4131. [CrossRef] [PubMed]
22. Li, J.; Su, Y.; Xia, W.; Qin, Y.; Humphries, M.J.; Vestweber, D.; Cabañas, C.; Lu, C.; Springer, T.A.
Conformational equilibria and intrinsic affinities define integrin activation. EMBO J. 2017, 36, 629–645.
[CrossRef] [PubMed]
23. Roggiani, F.; Mezzanzanica, D.; Rea, K.; Tomassetti, A. Guidance of signaling activations by cadherins and
integrins in epithelial ovarian cancer cells. Int. J. Mol. Sci. 2016, 17, 1387–1404. [CrossRef] [PubMed]
24. Sartori, A.; Portioli, E.; Battistini, L.; Calorini, L.; Pupi, A.; Vacondio, F.; Arosio, D.; Bianchini, F.;
Zanardi, F. Synthesis of novel c(AmpRGD)-Sunitinib dual conjugates as molecular tools targeting the
αvβ3 integrin/VEGFR2 couple and impairing tumor-associated angiogenesis. J. Med. Chem. 2017, 60,
248–262. [CrossRef] [PubMed]
25. Schwartz, M.A.; McRoberts, K.; Coyner, M.; Andarawewa, K.L.; Frierson, H.F., Jr.; Sanders, J.M.; Swenson, S.;
Markland, M.; Conaway, M.R.; Theodorescu, D. Integrin agonists as adjuvants in chemotherapy for
melanoma. Clin. Cancer Res. 2008, 14, 6193–6197. [CrossRef] [PubMed]
26. Humphries, M.J. Integrin cell adhesion receptors and the concept of agonism. Trends Pharmacol. Sci. 2000, 21,
29–32. [CrossRef]
27. Simon, D.I. Opening the field of integrin biology to “biased agonism”. Circ. Res. 2011, 109, 1199–1201.
[CrossRef] [PubMed]
28. Violin, J.D.; Lefkowitz, R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors.
Trends Pharmacol. Sci. 2007, 28, 416–422. [CrossRef] [PubMed]
29. Faridi, M.H.; Altintas, M.M.; Gomez, C.; Duque, J.C.; Vazquez-Padron, R.I.; Gupta, V. Small molecule agonists
of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than
activating antibodies in reducing vascular injury. Biochim. Biophys. Acta 2013, 1830, 3696–3710. [CrossRef]
[PubMed]
30. Dozynkiewicz, M.A.; Jamieson, N.B.; Macpherson, I.; Grindlay, J.; van den Berghe, P.V.; von Thun, A.;
Morton, J.P.; Gourley, C.; Timpson, P.; Nixon, C.; et al. Rab25 and CLIC3 collaborate to promote integrin
recycling from late endosomes/lysosomes and drive cancer progression. Dev. Cell. 2012, 22, 131–145.
[CrossRef] [PubMed]
31. Paul, N.R.; Allen, J.L.; Chapman, A.; Morlan-Mairal, M.; Zindy, E.; Jacquemet, G.; Fernandez del Ama, L.;
Ferizovic, N.; Green, D.M.; Howe, J.D.; et al. α5β1 integrin recycling promotes Arp2/3-independent cancer
cell invasion via the formin FHOD3. J. Cell Biol. 2015, 210, 1013–1031. [CrossRef] [PubMed]
Cancers 2017, 9, 78 16 of 18
32. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: The First Anti-Angiogenic Small Molecule Drug
Candidate. Design, Synthesis and Clinical Evaluation Anticancer Agents. Med. Chem. 2010, 10, 753–768.
[CrossRef]
33. Millard, M.; Odde, S.; Neamati, N. Integrin Targeted Therapeutics. Theranostics 2011, 1, 154–188. [CrossRef]
[PubMed]
34. Miller, L.M.; Pritchard, J.M.; Macdonald, S.J.F.; Jamieson, C.; Watson, A.J.B. Emergence of Small-Molecule
Non-RGD-Mimetic Inhibitors for RGD Integrins. J. Med. Chem. 2017, 60, 3241–3251. [CrossRef] [PubMed]
35. De Marco, R.; Tolomelli, A.; Juaristi, E.; Gentilucci, L. Integrin Ligands with α/β-Hybrid Peptide Structure:
Design, Bioactivity, and Conformational Aspects. Med. Res. Rev. 2016, 36, 389–424. [CrossRef] [PubMed]
36. Stupp, R.; Hegi, M.E.; Gorlia, T.; Erridge, S.C.; Perry, J.; Hong, Y.-K.; Aldape, K.D.; Lhermitte, B.; Pietsch, T.;
Grujicic, D.; et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMTpromoter (CENTRIC EORTC 26071–22072 study): A multicentre,
randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15, 1100–1108. [CrossRef]
37. Reynolds, A.R.; Hart, I.-R.; Watson, A.R.; Welti, J.C.; Silva, R.G.; Robinson, S.D.; Da Violante, G.;
Gourlaouen, M.; Salih, M.; Jones, M.C.; et al. Stimulation of tumor growth and angiogenesis by
lowconcentrations of RGD-mimetic integrin inhibitors. Nat. Med. 2009, 15, 392–400. [CrossRef] [PubMed]
38. Legler, D.F.; Wiedle, G.F.; Ross, F.P.; Imhof, B.A. Superactivation of integrin αvβ3 by low antagonist
Concentrations. J. Cell Sci. 2001, 114, 1545–1553. [PubMed]
39. Paladino, A.; Civera, M.; Belvisi, L.; Colombo, G. High affinity vs. native fibronectin in the modulation
of αvβ3 integrin conformational dynamics: Insights from computational analyses and implications for
molecular design. PLoS Comput. Biol. 2017, 13, e1005334. [CrossRef] [PubMed]
40. Aizpurua, J.M.; Ganboa, J.L.; Palomo, C.; Loinaz, I.; Oyarbide, J.; Fernandez, X.; Balentovà, E.; Fratila, R.M.;
Jiménez, A.; Miranda, J.I.; et al. Cyclic RGD beta-lactam peptidomimetics induce differential gene expression
in human endothelial cells. ChemBioChem 2011, 12, 401–405. [CrossRef] [PubMed]
41. Narasimhan, S.K.; Sejwal, P.; Zhu, S.; Luk, Y. Enhanced cell adhesion andmature intracellular structure
promoted by squaramide-based RGD mimics on bioinert surfaces. Bioorg. Med. Chem. 2013, 21, 2210–2216.
[CrossRef] [PubMed]
42. Hersel, U.; Dahmen, C.; Kessler, H. RGD modified polymers: Biomaterials for stimulated cell adhesion and
beyond. Biomaterials 2003, 24, 4385–4441. [CrossRef]
43. Fraioli, R.; Rechenmacher, F.; Neubauer, S.; Manero, J.M.; Gil, J.; Kessler, H.; Mas-Moruno, C. Mimicking bone
extracellular matrix: Integrin-binding peptidomimetics enhance osteoblast-like cells adhesion, proliferation,
and differentiation on titanium. Colloids Surf. B 2015, 128, 191–200. [CrossRef] [PubMed]
44. Galletti, P.; Soldati, R.; Pori, M.; Durso, M.; Tolomelli, A.; Gentilucci, L.; Dattoli, S.D.; Baiula, M.;
Spampinato, S.M.; Giacomini, D. Targeting integrins αvβ3 and α5β1 with new β-lactam derivatives. Eur. J.
Med. Chem. 2014, 83, 284–293. [CrossRef] [PubMed]
45. Baiula, M.; Galletti, P.; Martelli, G.; Soldati, R.; Belvisi, L.; Civera, M.; Dattoli, S.D.; Spampinato, S.M.;
Giacomini, D. New β-lactam derivatives modulate cell adhesion and signaling mediated by RGD-binding
and leukocyte integrins. J. Med. Chem. 2016, 59, 9721–9742. [CrossRef] [PubMed]
46. Tolomelli, A.; Gentilucci, L.; Mosconi, E.; Viola, A.; Dattoli, S.D.; Baiula, M.; Spampinato, S.; Belvisi, L.;
Civera, M. Development of isoxazoline-containing peptidomimetics as dual αvβ3 and α5β1 integrin ligands.
ChemMedChem. 2011, 6, 2264–2272. [CrossRef] [PubMed]
47. Brooks, P.C.; Strömblad, S.; Sanders, L.C.; von Schalscha, T.L.; Aimes, R.T.; Stetler-Stevenson, W.G.;
Quigley, J.P.; Cheresh, D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive
cells by interaction with integrin alpha v beta 3. Cell 1996, 85, 683. [CrossRef]
48. Boger, D.L.; Goldberg, J.; Silletti, S.; Kessler, T.; Cheresh, D.A. Identification of a novel class of small-molecule
antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the
binding and localization of proteinase MMP2 to integrin αvβ3. J. Am. Chem. Soc. 2001, 123, 1280–1288.
[CrossRef] [PubMed]
49. Silletti, S.; Kessler, T.; Goldberg, J.; Boger, D.L.; Cheresh, D.A. Disruption of matrix metalloproteinase 2
binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl.
Acad. Sci. USA 2001, 2, 119–124. [CrossRef]
50. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867. [CrossRef] [PubMed]
51. Rakoff-Nahoum, S. Why cancer and inflammation? Yale J. Biol. Med. 2006, 79, 123–130. [PubMed]
Cancers 2017, 9, 78 17 of 18
52. Avraamides, C.J.; Garmy-Susini, B.; Varner, J.A. Integrins in angiogenesis and lymphangiogenesis.
Nat. Rev. Cancer 2008, 8, 604–617. [CrossRef] [PubMed]
53. Middle, S.A.; Coupland, S.E.; Taktak, A.; Kidgell, V.; Slupsky, J.R.; Pettitt, A.R.; Till, K.J. Immunohistochemical
analysis indicates that the anatomical location of B-cell non-Hodgkin’s lymphoma is determined
by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.
Exp. Hematol. Oncol. 2015, 4, 10. [CrossRef] [PubMed]
54. Shain, K.H.; Tao, J. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug
resistance in B-cell malignancies. Oncogene 2014, 33, 4107–4113. [CrossRef] [PubMed]
55. Takeichi, T.; Mocevicius, P.; Deduchovas, O.; Salnikova, O.; Castro-Santa, E.; Büchler, M.W.; Schmidt, J.;
Ryschich, E. αLβ2 Integrin is indispensable for CD81 T-cell recruitment in experimental pancreatic and
hepatocellular cancer. Int. J. Cancer 2012, 130, 2067–2076. [CrossRef] [PubMed]
56. Suojanen, J.; Salo, T.; Sorsa, T.; Koivunen, E. αMβ2 Integrin modulator exerts antitumor activity in vivo.
Anticancer Res. 2007, 27, 3775–3782. [PubMed]
57. Lee, J.O.; Rieu, P.; Arnout, M.A.; Liddington, R.C. Crystal structure of the A domain from the alpha subunit
of integrin CR3 (CD11b/CD18). Cell 1995, 80, 631–638. [CrossRef]
58. Lee, J.O.; Bunkston, L.A.; Arnout, M.A.; Liddington, R.C. Two conformations of the integrin A-domain
(I-domain): A pathway for activation? Structure 1995, 3, 1333–1340. [CrossRef]
59. Shimaoka, M.; Salas, A.; Yang, W.; Weitz-Schmidt, G.; Springer, T.A. Small molecule integrin antagonists
that bind to the β-2 subunit I-like domain and activate signals in one direction and block them in the other.
Immunity 2003, 19, 391–402. [CrossRef] [PubMed]
60. Kuijpers, T.W.; Mul, E.P.; Bolm, M.; Kovach, N.L.; Gaeta, F.C.; Tollefson, V.; Elices, M.J.; Harlan, J.M. Freezing
adhesion molecules in a state of high-avidity binding blocks eosinophil migration. J. Exp. Med. 1993, 178,
279–284. [CrossRef] [PubMed]
61. Björklund, M.; Aitio, O.; Stefanidakis, M.; Suojanen, J.; Salo, T.; Sorsa, T.; Koivunen, E. Stabilization of the
activated αMβ2 integrin by a small molecule inhibits leukocyte migration and recruitment. Biochemistry
2006, 45, 2862–2871. [CrossRef] [PubMed]
62. Park, J.; Arnaout, M.A.; Gupta, V. A Simple, no-wash cell adhesion–based high-throughput assay for the
discovery of small-molecule regulators of the integrin CD11b/CD18. J. Biomol. Screen. 2007, 12, 406–417.
[CrossRef] [PubMed]
63. Faridi, M.H.; Maiguel, D.; Barth, C.J.; Stoub, D.; Day, R.; Schürer, S.; Gupta, V. Identification of novel agonists
of the integrin CD11b/CD18. Bioorg. Med. Chem. Lett. 2009, 19, 6902–6906. [CrossRef] [PubMed]
64. Maiguel, D.; Faridi, M.H.; Wei, C.; Kuwano, Y.; Balla, K.M.; Hernandez, D.; Barth, C.J.; Lugo, G.; Donnelly, M.;
Nayer, A.; et al. Small Molecule–Mediated Activation of the Integrin CD11b/CD18 Reduces Inflammatory
Disease. Sci. Signal 2011, 4, ra57. [CrossRef] [PubMed]
65. Celik, E.; Faridi, M.H.; Kumar, V.; Deep, S.; Moy, V.T.; Gupta, V. Agonist leukadherin-1 increases
cd11b/cd18-dependent adhesion via membrane tethers. Biophys. J. 2013, 105, 2517–2527. [CrossRef]
[PubMed]
66. Jagarapu, J.; Kelchtermans, J.; Rong, M.; Chen, S.; Hehre, D.; Hummler, S.; Farisi, M.H.; Gupta, V.; Wu, S.
Efficacy of leukadherin-1 in the prevention of hyperoxia-induced lung injury in neonatal rats. Am. J. Respir.
Cell Mol. Biol. 2015, 53, 793–801. [CrossRef] [PubMed]
67. Khan, S.Q.; Guo, L.; Cimbaluk, D.J.; Elshabrawy, H.; Faridi, M.H.; Jolly, M.; George, J.F.; Agarwal, A.;
Gupta, V. A small molecule β2 integrin agonist improves chronic kidney allograft survival by reducing
leukocyte recruitment and accompanying vasculopathy. Front. Med. 2014, 1, 45. [CrossRef] [PubMed]
68. Yang, W.; Carman, C.V.; Kim, M.; Salas, A.; Shimaoka, M.; Springer, T. A Small molecule agonist of an integrin,
αLβ2. J. Biol. Chem. 2006, 281, 37904–37912. [CrossRef] [PubMed]
69. Gadek, T.R.; Burdick, D.J.; McDowell, R.S.; Stanley, M.S.; Marsters, J.C.; Paris, K.J.; Oare, D.A.; Reynolds, M.E.;
Ladner, C.; Zioncheck, K.A.; et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1
immunoregulatory epitope to a small molecule. Science 2002, 295, 1086–1089. [CrossRef] [PubMed]
70. Mancuso, R.V.; Welzenbach, K.; Steinberger, P.; Krähenbühl, S.; Weitz-Schmidt, G. Downstream effect profiles
discern different mechanisms of integrin αLβ2 inhibition. Biochem. Pharm. 2016, 119, 42–55. [CrossRef]
[PubMed]
Cancers 2017, 9, 78 18 of 18
71. Hintersteiner, M.; Kallen, J.; Schmied, M.; Graf, C.; Jung, T.; Mudd, G.; Shave, S.; Gstach, H.; Auer, M.
Identification and X-ray Co-crystal Structure of a Small-Molecule Activator of LFA-1-ICAM-1 Binding.
Angew. Chem. Int. Ed. 2014, 53, 4322–4326. [CrossRef] [PubMed]
72. Yu, Y.; Zhu, J.; Mi, L.Z.; Walz, T.; Sun, H.; Chen, J.; Springer, T.A. Structural specializations of α4β7, an integrin
that mediates rolling adhesion. J. Cell. Biol. 2012, 196, 131–136. [CrossRef] [PubMed]
73. Vanderslice, P.; Biediger, R.J.; Woodside, D.G.; Brown, W.S.; Khounlo, S.; Warier, N.D.; Gundlach, C.W., IV;
Caivano, A.R.; Bornmann, W.G.; Maxwell, D.S.; et al. Small molecule agonist of very late antigen-4 (VLA-4)
integrin induces progenitor cell adhesion. J. Biol. Chem. 2013, 288, 19414–19428. [CrossRef] [PubMed]
74. Xiong, J.P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S.L.; Arnaout, M.A. Crystal structure
of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296,
151–155. [CrossRef] [PubMed]
75. Liu, J.; Narsinh, K.H.; Lan, F.; Wang, L.; Nguyen, P.K.; Hu, S.; Lee, A.; Han, L.; Gong, Y.; Huang, M.; et al.
Early stem cell engraftment predicts late cardiac functional recovery: Preclinical insights from molecular
imaging. Circ. Cardiovasc. Imaging 2012, 5, 481–490. [CrossRef] [PubMed]
76. Vrtovec, B.; Poglajen, G.; Lezaic, L.; Sever, M.; Domanovic, D.; Cernelc, P.; Socan, A.; Schrepfer, S.;
Torre-Amione, G.; Haddad, F.; Wu, J.C. Effects of intracoronary CD34+ stem cell transplantation in
nonischemic dilated cardiomyopathy patients: 5-year follow up. Circ. Res. 2013, 112, 165–173. [CrossRef]
[PubMed]
77. Taniguchi, Y.; Ido, H.; Sanzen, N.; Hayashi, M.; Sato-Nishiuchi, R.; Futaki, S.; Sekiguchi, K. The C-terminal
region of laminin beta chains modulates the integrin binding affinities of laminins. J. Biol. Chem. 2009, 284,
7820–7831. [CrossRef] [PubMed]
78. Ramovs, V.; Te Molder, L.; Sonnenberg, A. The opposing roles of laminin-binding integrins in cancer.
Matrix Biol. 2017, 57–58, 213–243. [CrossRef] [PubMed]
79. Subbaram, S.; Dipersio, C.M. Integrin α3β1 as a breast cancer target. Expert Opin. Ther. Targets 2011, 15,
1197–1210. [CrossRef] [PubMed]
80. Lee, H.W.; Khan, S.Q.; Faridi, M.H.; Wei, C.; Tardi, N.J.; Altintas, M.M.; Elshabrawy, H.A.; Mangos, S.;
Quick, K.L.; Sever, S.; et al. A podocyte-based automated screening assay identifies protective small
molecules. J. Am. Soc. Nephrol. 2015, 26, 2741–2752. [CrossRef] [PubMed]
81. Xu, Y.; Zhu, X.; Hahm, H.S.; Wei, W.; Hao, E.; Hayek, A.; Ding, S. Revealing a core signalling regulatory
mechanism for pluripotent stem cell survival and self-renewal by small molucules. Proc. Natl. Acad. Sci. USA
2010, 107, 8129–8134. [CrossRef] [PubMed]
82. Shah, B.S.; Chen, M.; Suzuki, T.; Embree, M.; Kong, K.; Lee, C.H.; He, L.; Xiang, L.; Ahn, J.A.; Ding, S.;
Mao, J.J. Pyrintegrin induces soft tissue formation by transplanted or endogenous cells. Sci. Rep. 2017, 7,
36402. [CrossRef] [PubMed]
83. Zeltz, C.; Gullberg, D. The integrin–collagen connection—a glue for tissue repair? J. Cell Sci. 2016, 129,
653–664. [CrossRef] [PubMed]
84. Chung, C.-H.; Lin, K.-T.; Chang, C.-H.; Peng, H.-C.; Hua, T.-F. The integrin α2β1 agonist, aggretin, promotes
proliferation and migration of VSMC through NF-kB translocation and PDGF production. Brit. J. Pharmacol.
2009, 156, 846–856. [CrossRef] [PubMed]
85. Chung, C.-H.; Chang, C.-H.; Hsu, C.C.; Lin, K.T.; Peng, H.-C.; Hua, T.-F. Aggretin Venom Polypeptide as
a Novel Anti-angiogenesis Agent by Targeting Integrin α2β1. Sci. Rep. 2017, 7, 43612. [CrossRef] [PubMed]
86. Doyle, A.D.; Carvajal, N.; Jin, A.; Matsumoto, K.; Yamada, K.M. Local 3D matrix microenvironment regulates
cell migration through spatiotemporal dynamics of contractility-dependent adhesions. Nat. Commun. 2015,
6, 1–15. [CrossRef] [PubMed]
87. Ritsma, L.; Dey-Guha, I.; Talele, N.; Salony, X.S.; Chowdhury, J.; Ross, K.N.; Ramaswamy, S. Integrin β1
activation induces an antimelanoma host response. PLoS ONE 2017, 12, e0175300. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
